BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia
Lena Schmidlechner(University Hospital Schleswig-Holstein), Meike Kaehler(University Hospital Schleswig-Holstein)
Cited by 1
Related Papers
Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia
|Frontiers in Cell and Developmental Biology|2025|1
The role of the lysine histone methylase KMT2D in chronic myeloid leukemia
|Frontiers in Pharmacology|2025|0